Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag
M R
MR
Roblin
P M
PM
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000188:drug therapy*; D016993:Chlamydophila pneumoniae / Q000187:drug effects; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin